by Grow Up Conference | Jul 22, 2024 | Cannabis News Wire, Media Partners
The recent decision by the U.S. Supreme Court to limit the power of federal regulatory agencies has introduced new uncertainty regarding the future of cannabis rescheduling. However, administrative law and policy experts believe that the ambiguity is not expected to hinder the Biden administration’s reclassification process.
In a 6-to-3 decision last Friday, the court ruled that courts are no longer obligated to follow federal agencies’ interpretations of statutes when Congress leaves those interpretations unclear. This ruling effectively ends the Chevron doctrine, named after a 1984 judgment. Historically, courts would defer to regulators as the subject matter experts.
There is speculation about the implication of the Chevron ruling on state-licensed cannabis markets, with questions arising about the future ability of federal agencies to provide nonbinding guidance, such as a new Cole memo. Further, doubts have surfaced regarding the U.S. Drug Enforcement Administration’s (DEA) authority over intoxicating hemp products such as delta-8 THCA and THC.
Paradoxically, the dependence of courts on the Chevron doctrine has hampered earlier attempts to reschedule cannabis. This reliance enabled the DEA to utilize its own criteria in determining that cannabis did not have a recognized medical use.
However, in the ongoing rescheduling process initiated by President Joseph Biden in 2022, the U.S. Department of Health and Human Services (HHS) determined in August 2023 that marijuana does have a recognized medical use based on a new two-part standard. Acting on this advice and an opinion from the U.S. Department of Justice’s (DOJ) Office of Legal Counsel, Merrick Garland, the U.S. attorney general, proposed a rule in May to reschedule cannabis in Schedule III of the CSA.
Chief Justice Roberts noted in his 35-page opinion that federal law requires courts to use their own discretion to decide legal disputes rather than relying on administrative bodies to make decisions.
Other concerns regarding the DOJ’s analysis, which suggests that U.S. responsibilities under international treaties prevent rescheduling, are also covered in the ruling decision. There will likely be legal challenges referencing the ruling in regard to the rescheduling process.
It’s unlikely that ongoing legal actions, including one contesting the legality of the federal marijuana ban, will be immediately impacted by the ruling.
According to former Massachusetts state regulator and attorney Shaleen Title, predictions that the verdict could be used to challenge state marijuana legislation regarding licensing or social justice requirements are, at best, speculative. Meanwhile, others suggested that states might adapt their deference policies in response to the Supreme Court’s ruling, potentially weakening deference and empowering state courts to set standards for marijuana businesses.
The regulatory landscape for marijuana in the United States is still very much in flux, and leading actors such as SNDL Inc. (NASDAQ: SNDL) have plenty to digest, ranging from court decisions that set precedents to state and federal regulations, as they work to operate within established legal boundaries while going about their legitimate business activities.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Jul 22, 2024 | Media Partners, Stratcann
Tilray has received the first cannabis cultivation licence issued under Germany’s new Cannabis Act.
The American cannabis company, which operates in Canada, the United States, Europe, Australia, and Latin America, made the announcement on July 22. Tilray’s Aphria RX Facility in Germany was the first to receive such a licence in the country.
In February, Germany passed the German Medical Cannabis Act, expanding the country’s medical cannabis laws. Aphria RX has been present in the medical cannabis space in Germany since March 2019, when the company was awarded a license for the cultivation of medical cannabis in Germany from the German Federal Institute for Drugs and Medical Devices (the “BfArM”).
At the time, the licence allowed for a total of five lots (1,000 kgs) and was the only licensed producer in Germany with permission to grow all three strains of medical cannabis approved by the BfArM.
The new licence, made possible by recent legislative changes in Germany that increased the number of patients and subscribers for cannabis for medicinal purposes, allows the Aphria RX facility to expand its growing capacity. Rather than growing just three cultivars for patients, the company can now grow and sell up to 31.
Tilray says its growing rooms were designed by Kevin Anderson, the master grower behind Tilray subsidiary Broken Coast, located on Vancouver Island in British Columbia, Canada.
“We are thrilled to receive this license as it will provide greater access to some of the highest quality medical cannabis produced in Germany and enable us to expand the range of treatment options available to patients,” says Denise Faltischek, Tilray’s Chief Strategy Officer and Head of International, in a press release. “We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care.”
Germany legalized cannabis this past March, with the law coming into effect in stages. On April 1, personal possession and cultivation became legal. On July 1, the country began allowing cannabis growing clubs. However, the country does not allow the sale of cannabis, except for medical purposes. That bill also made amendments to the country’s medical cannabis laws (MedCanG), paving the way for Tilray’s most recent announcement.
Germany first legalized cannabis flowers for medical purposes in 2017. Although annual domestic production was capped at 10,400 kg, since that time, the amount of cannabis prescribed under the program has steadily increased, fed by imports from countries like Canada. In the first three quarters of 2017, there were just 530 kg of cannabis imported into Germany. By the completion of the first three quarters of 2023, that increased to 14,315 kg
The new licence will allow Germany to better address that growing demand through domestic supply. Anyone who wishes to cultivate, produce, trade, import, export, dispense, sell, otherwise place on the market, obtain or acquire cannabis for medicinal purposes or cannabis for medical-scientific purposes requires a permit from the German Federal Institute for Drugs and Medical Devices.
In addition to Tilray, Canadian cannabis company Aurora and the German company Demecan were first allowed to grow a combined total of 10,400kg of medical cannabis in Germany beginning in 2019.
Reliable data are still lacking, but it is conceivable that the growing demand for medical cannabis is to some degree, driven by people using the drug exclusively or partially for recreational purposes.
by Grow Up Conference | Jul 22, 2024 | Grow Opportunity, Media Partners
by Grow Up Conference | Jul 22, 2024 | Grow Opportunity, Media Partners
by Grow Up Conference | Jul 22, 2024 | Grow Opportunity, Media Partners
by Grow Up Conference | Jul 22, 2024 | Grow Opportunity, Media Partners
by Grow Up Conference | Jul 22, 2024 | Cannabis News Wire, Media Partners
- Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2
- The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug
- For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream
- Results from the GLP-1-H24-2 study are set to be announced in late August or early September
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. The potential of effective oral delivery of GLP -1 drugs, a class of drugs used to address diabetes and weight loss, represents a vast global market potential for DehydraTECH.
Blood samples collected throughout the study have been transported to the bioanalytical lab for analysis, and the organization looks to complete the analysis and announce the results in late August or early September.
“Lexaria is delighted that our contracted clinical research organization was able to complete the active phase of the study on schedule,” noted Chris Bunka, Lexaria’s CEO. “The results of this Study are expected to validate our earlier work with semaglutide, and also to discover whether it is possible to achieve any absorption of this market-leading GLP-1 drug through the tissues of the mouth,” he added (https://cnw.fm/cFdVf).
This study explored tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug. It also sought to measure blood glucose and insulin levels, highlighting the drug’s potential in treating diabetes and weight loss. The study comprised three primary arms, each of which compared three 7mg semaglutide dose formulations. The first arm was a positive control of Rybelsus(R), the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. The second arm saw the use of Lexaria’s patented DehydraTECH technology in processing semaglutide in swallowed tablets. The last arm was an in-mouth dissolvable DehydraTECH-semaglutide oral tablet, a first in the industry.
This final study arm will be the first to investigate whether DehydraTECH-enhanced semaglutide can be absorbed systemically at any level through the sublingual/buccal tissues of the mouth and throat with fewer side effects than swallowed administration. It takes into account the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in meager blood absorption rates of less than 1% when an absorption technology is not used.
Previous Lexaria studies have demonstrated improvements in the delivery of semaglutide into the bloodstream and in controlling blood sugar. They also demonstrated that DehydraTECH GLP-1 processed semaglutide is generally better tolerated than the Rybelsus(R) tablets themselves, with the latter often resulting in instances of moderate diarrhea and nausea. GLP-1-H24-2 looks to validate these results and more, further pointing to the superiority of its DehydraTECH technology and highlighting its potential in treating diabetes and weight loss.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Jul 22, 2024 | Cannabis News Wire, Media Partners
Congress federally legalized hemp when it approved the 2018 Farm Bill, making the use of hemp as well as its production legal. Legislators who supported the legalization of this industrial crop expected that it would be used for textiles and nonintoxicating supplements such as shelled hemp seeds and CBD oil.
What they didn’t realize, however, was that with some tweaking, hemp could also induce highs when consumed.
Currently, individuals in different parts of the country can get high on THC derived from hemp without breaking the law. These hemp-based intoxicants are every bit as strong as compounds derived from cannabis available in legal states. Individuals who have tried intoxicating compounds from both marijuana and hemp admit that their effects are identical.
To understand how we got here, we looked at basic information on these plants.
Marijuana and hemp are both plants of the genus Cannabis, which are further classified into the species sativa, and indica. Cannabinoids are chemical compounds obtained from Cannabis sativa, with researchers having identified roughly 100 cannabinoids that occur naturally.
Cannabinoids are classified into two categories: those that induce a high and those that don’t.
Hemp contains limited amounts of delta-9 THC and large amounts of CBD. On the other hand, marijuana has high levels of delta-9 THC. THC is one of the two primary compounds found in marijuana, the other being CBD. Unlike THC, CBD doesn’t induce a high when ingested.
In 1937, Congress banned both hemp and marijuana when it approved the Marihuana Tax Act. When this law was overturned by the Supreme Court in 1969, Congress enacted the Controlled Substances Act the following year, effectively outlawing marijuana, hemp and other substances such as psychedelics.
In the 1980s, Jack Herer, a cannabis enthusiast, published a book that discussed how hemp could replace timber and plastic in various applications without causing any harm to the environment and with fewer costs. This began a movement that, decades later, led to the passage of the 2018 Farm Bill.
The bill defines hemp as a Cannabis sativa plant and any part of it with a delta-9 THC concentration of 0.3% on a dry weight basis. While this looks straight forward, it appears that Congress wasn’t up-to-date on cannabinoid research.
As it turns out, one chemist had found a way to obtain delta-9 THC from CBD oil and another intoxicating cannabinoid dubbed delta-8 THC. With the farm bill’s definition in mind, it appeared that it wasn’t illegal to synthesize delta-8 THC from CBD, as long as the process began with a plant that had no more than 0.3% delta-9 THC.
This take was endorsed in 2022 in a ruling issued by the Ninth Circuit Court of Appeals. From this, one may not be far off to surmise that Congress may have accidentally legalized cannabis nationwide. However, marijuana entities such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) are likely to conduct their operations in accordance with state laws since they are less likely to be subject to controversy and conjecture.
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
by Grow Up Conference | Jul 20, 2024 | Garden Culture Magazine, Media Partners
The Goldenrod plant is a no-fuss plant that works overtime for the local ecosystem.
Where Does Goldenrod Grow?
The wildflower garden is in full bloom, and goldenrod is the star attraction. A native wildflower of North America, it grows everywhere, from the prairies to coastal landscapes. Hardy to -40°C, this plant stands out because of everything it does for the ecosystem.
Why Is Goldenrod So Important?
According to Pennsylvania State University, 11 species of native bees are specialists in goldenrod and seek it specifically for their diet. It’s a host plant for several butterfly and moth larvae. The high-quality pollen it produces is rich in protein, fats, and minerals and is critical for the endangered migratory monarch butterfly. For doing all that and still adding color and texture to the summer garden, this plant earns my respect as July’s Plant of the Month.
How To Care for Goldenrod
Goldenrod loves full sun, and if it refuses to bloom, it’s likely because it didn’t get enough time sunbathing. Goldenrod is drought-tolerant and thrives in rocky, sandy, or clay soil. Once established, the plant only needs occasional watering. Too much water can cause root rot and fungal disease. For a bushier plant, prune the stem tips in spring, and remember to deadhead spent flower heads to encourage more blossoms throughout the season.
Potential Problems With Goldenrod
Although goldenrod is a beacon for beneficial garden insects, it is also a haven for aphids and spider mites. A good rinse of water with the garden hose will eradicate the problem. Sadly, goldenrod has also developed a reputation for being invasive. If left undisturbed and allowed to colonize, the rhizomatous roots will continue to spread and create new plants. Combined with self-seeding flower heads, goldenrod is practically immortal in the garden.
To counter goldenrod’s desire to spread its wings, try growing it in large containers or remove the flower heads before they go to seed. Alternatively, dividing clumps every two or three years will keep the plant under control. To do this, dig it up and separate it, ensuring each section has a good portion of roots and a couple of growth tips. Replant the clumps throughout the garden.
How To Propagate Goldenrod
Besides dividing, you can propagate goldenrod by saving the seedheads and drying them in the fall to spread in the garden after all danger of frost is gone in the spring. Don’t cover the seeds, though, as they require a lot of light to germinate. You can also start goldenrod from cuttings. In the early summer, cut shoots from the base and plant them in a small container of regular potting mix. When you see new growth sprouting, transplant it into the garden.
Types of Goldenrod
There are over 100 varieties of goldenrod, including these popular selections:
-
Solidago caesia (blue-stemmed goldenrod) has arching purplish stems and is not an aggressive spreader.
-
Solidago odora (sweet goldenrod) is a 2-to4-foot non-aggressive plant with anise-scented leaves and yellow flower heads.
-
Solidago speciosa, or showy goldenrod, grows 1 to 3 feet tall with dense clusters of tiny yellow flowers
-
Baby Gold’ (Solidago canadensis hybrid) grows as a 2-to 3-foot plant, producing bright yellow flowers from mid-to-late summer.
-
Little Lemon (Solidago hybrida’Dansolitlem’) is compact (8 to 12 inches) with pale lemon flowers.
by Grow Up Conference | Jul 20, 2024 | Media Partners, Stratcann
This week at StratCann, we looked at Delta 9 receiving CCAA protection, while SNDL announced it was laying off 106 employees as part of a restructuring process.
We also dove into new cannabis sales figures from Stats Canada, the new adverse reports review from Health Canada, and cannabis clinical trials being hampered by a lack of GMP cannabis.
BC provided updates to its cannabis sampling rules, and the federal government responded to a recent edibles petition tabled in the House of Commons.
A cannabis farmgate store in Victoria moved one step closer to reality, and Purileaf recalled their Frank CBD Oil 100 due to a labelling error.
Lastly, Alberta and BC reached an agreement over wine sales. We point out that the cannabis industry has similar asks.
In other cannabis news
The town of Aurora, Ontario, is frustrated by a cannabis facility that continues to operate against municipal bylaws. The article says the business is i420.club, or the Toronto Cannabis Delivery Club, with more than 20 locations across the GTA. Since the dispute is a bylaw issue, York Regional Police are not involved, according to York Regional Police Const. James Dickson.
The owner of True North Cannabis in Cambridge, Ontario, says he is frustrated by the lack of enforcement against unlicensed stores by the Waterloo Regional Police Services.
Highlighting this ongoing issue in Ontario with unlicensed cannabis stores, one company shared a press release about a new delivery service for an unlicensed cannabis store in Kensington Market.
Council in Esterhazy, SK, denied a second cannabis store, citing concerns that its main street could be lined with cannabis stores. The town of about 2,300 residents currently has one cannabis store.
The Wheatland County Municipal Planning Commission refused a development permit for a cannabis store within the Hamlet of Gleichen, Alberta. The town is home to one cannabis store, the Gleichen Cannabis Store.
The National Post once again trotted out some rage-bait fan fiction about the “failure” of legalization that distorts and misrepresents real issues facing the industry with some boring, run-of-the-mill Trudeau-bad/taxes-bad nonsense.
Law enforcement
NL RCMP seized cannabis, cigarettes, and cash in Grand Falls-Windsor.
The OPP charged three people after executing two search warrants in Dunnville and Cayuga, seizing around $200,000 in cannabis, cannabis products, and currency on July 17.
On July 17, 2024, at approximately 6:00 a.m., officers from the East District in Winnipeg responded to a report of a Commercial break-in at a cannabis shop in the 1000 block of Henderson Highway.
Saskatchewan RCMP says they recently suspended 35 drivers for operating a vehicle under the influence of cannabis during a two-day check stop.
Canada Border Services reported 32 kg of cannabis seized at Halifax International Airport in a video shared on social media.
International cannabis news
A man from Ontario pleaded guilty to importing cannabis into Bermuda this past week. He was sentenced to 8.5 years for the 19.5 kilograms of cannabis found hidden in the lining of his baggage. Last week, a Canadian woman admitted in the Supreme Court that she smuggled a similar quantity into the island.
A New York court has thrown out a suit filed by investors in Canopy Growth Corp, arguing they failed to show that the cannabis producer’s executives had the necessary level of intent for securities fraud when they allegedly misrepresented the success of sports drink subsidiary BioSteel.
California has recalled several vape pens in recent weeks, including two this past week, for the presence of the pesticide chlorfenapyr.
A US federal judge refused to halt New York City’s crackdown on unlicensed sellers of cannabis, citing public safety concerns. New York City has closed 640 unlicensed smoke shops since early May, using enforcement powers under a new state law known as the Smokeout Act.
And finally, US Federal Court for the District of Massachusetts dismissed a case brought by a coalition of cannabis companies challenging the federal prohibition on cannabis.
Recent Comments